A Phase 1 interventional study of LT3001 drug product and Placebo in Acute Ischemic Stroke, sponsored by Lumosa Therapeutics Co., Ltd.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-02.
Sponsored by Lumosa Therapeutics Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 480 studies in Ischemic Stroke with a site in United States — 122 open to participants now, 146 under way, 13 of them phase 3. Ischemic Stroke · United States.
Among the 480 studies in Ischemic Stroke with a site in United States, this one is the 183rd largest by enrollment of the 364 interventional ones that give a count, is one of 37 that started in 2021, is one of 37 in phase 1, and was the 295th registered.
2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.
Browse Ischemic Stroke studies →122 of the 480 studies in Ischemic Stroke with a site in United States are open now. Recruiting first, the newest first:
Casa Colina Hospital and Centers for Healthcare · Sites in United States
Ages 18+
Magnetic Tides · Sites in United States
Ages 18–80
Vanderbilt University Medical Center · Sites in United States
Ages 18+
Abrexa Pharmaceuticals, Inc. · Sites in United States
Ages 18–90
Medtronic Neurovascular Clinical Affairs · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
480 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 56 · Phase 2 103 · Phase 3 46 · Phase 4 11
First in 1993; this study’s year is marked. 37 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 65 is below the median of 120 across 1,781 interventional studies indexed under Ischemic Stroke.
Median enrollment 66 across the 364 interventional studies, 300 across the 111 observational. Of the 281 that completed or were terminated, 128 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
154 of 480 have an industry lead sponsor. The 10 most frequent:
Lumosa Therapeutics Co., Ltd. is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Lumosa Therapeutics Co., Ltd. has 5 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
48 of the studies in Ischemic Stroke with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05065216Phase 3DiaMedica Therapeutics IncTreatment of Acute Ischemic Stroke (ReMEDy2 Trial) | 2026-12 |
| NCT03223220Phase 3Lower Merion Neurology Research FoundationQuelling of Excitotoxicity in Acute Stroke With Ketamine | 2026-12-31 |
| NCT05691244Phase 3Pharmazz, Inc.Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke | 2027-09 |
| NCT07649135University of MinnesotaFeasibility of a Remotely Delivered Step Count Intervention in Chronic Stroke | 2026-11-30 |
| NCT05085210Beth Israel Deaconess Medical CenterImproving Visual Field Deficits With Noninvasive Brain Stimulation | 2026-12 |
Add all 48 to your calendar (.ics) → With an account.
Among the 480 studies in Ischemic Stroke with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Phase 1 study is planned to establish the clinical safety and pharmacokinetics profile of multiple dose of LT3001 drug product and to investigate drug interactions of LT3001 with potential concomitant medications in healthy subjects.
This study is a two-part study. Part A is double-blind, placebo-controlled, and will examine the safety and PK profiles of multiple doses of LT3001 drug product in healthy subjects. Part B is open-label and will assess the safety and PK of LT3001 when coadministered with aspirin, clopidogrel, apixaban or dabigatran.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Multiple doses of LT3001 administered by intravenous infusion
Drug: LT3001 drug product
Multiple doses of Placebo administered by intravenous infusion
Drug: Placebo
Multiple doses of LT3001 and Aspirin administered
Drug: LT3001 drug product · Drug: Aspirin
Multiple doses of LT3001 and Clopidogrel administered
Drug: LT3001 drug product · Drug: Clopidogrel
Multiple doses of LT3001 and Apixaban administered
Drug: LT3001 drug product · Drug: Apixaban
Multiple doses of LT3001 and Dabigatran administered
Drug: LT3001 drug product · Drug: Dabigatran
Multiple doses of LT3001 drug product administered by intravenous infusion
Also known as: LT3001 injection
Multiple doses of Placebo administered by intravenous infusion
Also known as: Placebo of LT3001 drug product
Loading and maintenance doses of Aspirin administered by oral
Also known as: Aspirin tablet
Loading and maintenance doses of Clopidogrel administered by oral
Also known as: Clopidogrel tablet
Multiple doses of Apixaban administered by oral
Also known as: Eliquis®
Multiple doses of Dabigatran administered by oral
Also known as: Pradaxa®
Number of Adverse Events
To evaluate the safety and tolerability of LT3001 administered alone or in combination with aspirin, clopidogrel, apixaban, or dabigatran, as determined by the number and severity of adverse events collected from baseline through Day 4 post-baseline in Part A, and from baseline through Day 16 post-baseline in Part B.
Time frame: Adverse events were assessed from baseline through Day 4 post-baseline in Part A, and from baseline through Day 16 post-baseline in Part B.
Change From Baseline in Activated Partial Thromboplastin Time (APTT)
Change from baseline in activated partial thromboplastin time (APTT), measured in seconds, was assessed to evaluate the safety of LT3001 administered alone or in combination with aspirin, clopidogrel, apixaban, or dabigatran from baseline up to 16 days post-dose.
Time frame: 16 days
Number of Participants With Prolongation in Platelet Function Test
The outcome measured the number of participants with prolongation in platelet function test results following administration of LT3001 alone or in combination with aspirin, clopidogrel, apixaban, or dabigatran. Platelet function was assessed using collagen/epinephrine and collagen/ADP assays. Results were evaluated from baseline up to 16 days post-dose. Participants in the Part A placebo group did not undergo platelet function testing and were therefore not included in this outcome analysis.
Time frame: 16 days
Plasma PK Parameters of LT3001 - Cmax
Plasma concentrations of LT3001 and derived PK parameters up to 10 days after a single dose or multiple doses intravenous infusion of LT3001.
Time frame: Predose and post-dose time points up to 10 days after dosing
Plasma PK Parameters of LT3001 - Tmax
Plasma concentrations of LT3001 and derived PK parameters up to 10 days after a single dose or multiple doses intravenous infusion of LT3001.
Time frame: 10 days
Plasma PK Parameters of LT3001 - AUC
Plasma concentrations of LT3001 and derived PK parameters up to 10 days after a single dose or multiple doses intravenous infusion of LT3001.
Time frame: 10 days
Plasma PK Parameters of Aspirin - Cmax
Plasma concentrations of Aspirin and derived PK parameters up to 8 days after multiple doses of Aspirin were administered.
Time frame: 8 days
Plasma PK Parameters of Aspirin - Tmax
Plasma concentrations of Aspirin and derived PK parameters up to 8 days after multiple doses of Aspirin were administered.
Time frame: 8 days
Plasma PK Parameters of Aspirin - AUC
Plasma concentrations of Aspirin and derived PK parameters up to 8 days after multiple doses of Aspirin were administered.
Time frame: 8 days
Plasma PK Parameters of Clopidogrel - Cmax
Plasma concentrations of Clopidogrel and derived PK parameters up to 10 days after multiple doses of Clopidogrel were administered.
Time frame: 10 days
Plasma PK Parameters of Clopidogrel - Tmax
Plasma concentrations of Clopidogrel and derived PK parameters up to 10 days after multiple doses of Clopidogrel administered (alone or with LT3001).
Time frame: 10 days
Plasma PK Parameters of Clopidogrel - AUC
Plasma concentrations of Clopidogrel and derived PK parameters up to 10 days after multiple doses of Clopidogrel were administered.
Time frame: 10 days
Plasma PK Parameters of Apixaban - Cmax
Plasma concentrations of Apixaban and derived PK parameters up to 8 days after multiple doses of Apixaban were administered.
Time frame: 8 days
Plasma PK Parameters of Apixaban - Tmax
Plasma concentrations of Apixaban and derived PK parameters up to 8 days after multiple doses of Apixaban were administered.
Time frame: 8 days
Plasma PK Parameters of Apixaban - AUC
Plasma concentrations of Apixaban and derived PK parameters up to 8 days after multiple doses of Apixaban were administered.
Time frame: 8 days
Plasma PK Parameters of Dabigatran - Cmax
Plasma concentrations of Dabigatran and derived PK parameters up to 8 days after multiple doses of Dabigatran were administered.
Time frame: 8 days
Plasma PK Parameters of Dabigatran - Tmax
Plasma concentrations of Dabigatran and derived PK parameters up to 8 days after multiple doses of Dabigatran administered (alone or with LT3001).
Time frame: 8 days
Plasma PK Parameters of Dabigatran - AUC
Plasma concentrations of Dabigatran and derived PK parameters up to 8 days after multiple doses of Dabigatran administered (alone or with LT3001).
Time frame: 8 days
| Milestone | Part A - LT3001 Drug Product | Part A - Placebo | Part B - LT3001 and Aspirin | Part B - LT3001 and Clopidogrel | Part B - LT3001 and Apixaban | Part B - LT3001 and Dabigatran |
|---|---|---|---|---|---|---|
| Started | 12 | 4 | 13 | 12 | 12 | 12 |
| Completed | 12 | 4 | 12 | 12 | 12 | 12 |
| Not completed | 0 | 0 | 1 | 0 | 0 | 0 |
To evaluate the safety and tolerability of LT3001 administered alone or in combination with aspirin, clopidogrel, apixaban, or dabigatran, as determined by the number and severity of adverse events collected from baseline through Day 4 post-baseline in Part A, and from baseline through Day 16 post-baseline in Part B.
| event | Part A - LT3001 Drug Product | Part A - Placebo | Part B - LT3001 and Aspirin | Part B - LT3001 and Clopidogrel | Part B - LT3001 and Apixaban | Part B - LT3001 and Dabigatran |
|---|---|---|---|---|---|---|
| Number of Adverse Events | 3 | 0 | 2 | 2 | 2 | 1 |
Change from baseline in activated partial thromboplastin time (APTT), measured in seconds, was assessed to evaluate the safety of LT3001 administered alone or in combination with aspirin, clopidogrel, apixaban, or dabigatran from baseline up to 16 days post-dose.
| second | Part A - LT3001 Drug Product | Part A - Placebo | Part B - LT3001 and Aspirin | Part B - LT3001 and Clopidogrel | Part B - LT3001 and Apixaban | Part B - LT3001 and Dabigatran |
|---|---|---|---|---|---|---|
| Change From Baseline in Activated Partial Thromboplastin Time (APTT) | -0.62 ± 0.888 | -0.58 ± 0.830 | 2.62 ± 5.576 | 1.75 ± 3.349 | 0.009 ± 1.407 | 6.83 ± 4.003 |
The outcome measured the number of participants with prolongation in platelet function test results following administration of LT3001 alone or in combination with aspirin, clopidogrel, apixaban, or dabigatran. Platelet function was assessed using collagen/epinephrine and collagen/ADP assays. Results were evaluated from baseline up to 16 days post-dose. Participants in the Part A placebo group did not undergo platelet function testing and were therefore not included in this outcome analysis.
| Participants | Part A - LT3001 Drug Product | Part B - LT3001 and Aspirin | Part B - LT3001 and Clopidogrel | Part B - LT3001 and Apixaban | Part B - LT3001 and Dabigatran |
|---|---|---|---|---|---|
| collagen/epinephrine | 0 | 1 | 1 | 0 | 0 |
| collagen/ADP | 1 | 5 | 4 | 0 | 2 |
Plasma concentrations of LT3001 and derived PK parameters up to 10 days after a single dose or multiple doses intravenous infusion of LT3001.
| ng/mL | Part A - LT3001 Drug Product | Part B - LT3001 and Aspirin | Part B - LT3001 and Clopidogrel | Part B - LT3001 and Apixaban | Part B - LT3001 and Dabigatran |
|---|---|---|---|---|---|
| Plasma PK Parameters of LT3001 - Cmax | 48.86 ± 17.06 | 45.30 ± 12.31 | 43.23 ± 9.569 | 42.28 ± 15.62 | 43.96 ± 12.57 |
Plasma concentrations of LT3001 and derived PK parameters up to 10 days after a single dose or multiple doses intravenous infusion of LT3001.
| hour | Part A - LT3001 Drug Product | Part B - LT3001 and Aspirin | Part B - LT3001 and Clopidogrel | Part B - LT3001 and Apixaban | Part B - LT3001 and Dabigatran |
|---|---|---|---|---|---|
| Plasma PK Parameters of LT3001 - Tmax | 0.22 ± 0.054 | 0.18 ± 0.073 | 0.21 ± 0.054 | 0.24 ± 0.057 | 0.21 ± 0.043 |
Plasma concentrations of LT3001 and derived PK parameters up to 10 days after a single dose or multiple doses intravenous infusion of LT3001.
| h*ng/mL | Part A - LT3001 Drug Product | Part B - LT3001 and Aspirin | Part B - LT3001 and Clopidogrel | Part B - LT3001 and Apixaban | Part B - LT3001 and Dabigatran |
|---|---|---|---|---|---|
| Plasma PK Parameters of LT3001 - AUC | 11.87 ± 3.364 | 9.820 ± 3.002 | 10.21 ± 2.073 | 10.32 ± 3.173 | 9.769 ± 2.558 |
Plasma concentrations of Aspirin and derived PK parameters up to 8 days after multiple doses of Aspirin were administered.
| ng/mL | Part B - LT3001 and Aspirin |
|---|---|
| Plasma PK Parameters of Aspirin - Cmax | 477 ± 362.5 |
Plasma concentrations of Aspirin and derived PK parameters up to 8 days after multiple doses of Aspirin were administered.
| hour | Part B - LT3001 and Aspirin |
|---|---|
| Plasma PK Parameters of Aspirin - Tmax | 3.7 ± 2.3 |
Plasma concentrations of Aspirin and derived PK parameters up to 8 days after multiple doses of Aspirin were administered.
| h*ng/mL | Part B - LT3001 and Aspirin |
|---|---|
| Plasma PK Parameters of Aspirin - AUC | 1709 ± 1251 |
Plasma concentrations of Clopidogrel and derived PK parameters up to 10 days after multiple doses of Clopidogrel were administered.
| ng/mL | Part B - LT3001 and Clopidogrel |
|---|---|
| Plasma PK Parameters of Clopidogrel - Cmax | 3.925 ± 1.991 |
Plasma concentrations of Clopidogrel and derived PK parameters up to 10 days after multiple doses of Clopidogrel administered (alone or with LT3001).
| hour | Part B - LT3001 and Clopidogrel |
|---|---|
| Plasma PK Parameters of Clopidogrel - Tmax | 2.0 ± 1.0 |
Plasma concentrations of Clopidogrel and derived PK parameters up to 10 days after multiple doses of Clopidogrel were administered.
| h*ng/mL | Part B - LT3001 and Clopidogrel |
|---|---|
| Plasma PK Parameters of Clopidogrel - AUC | 8.255 ± 5.129 |
Plasma concentrations of Apixaban and derived PK parameters up to 8 days after multiple doses of Apixaban were administered.
| ng/mL | Part B - LT3001 and Apixaban |
|---|---|
| Plasma PK Parameters of Apixaban - Cmax | 188.5 ± 76.11 |
Plasma concentrations of Apixaban and derived PK parameters up to 8 days after multiple doses of Apixaban were administered.
| hour | Part B - LT3001 and Apixaban |
|---|---|
| Plasma PK Parameters of Apixaban - Tmax | 3.1 ± 1.5 |
Plasma concentrations of Apixaban and derived PK parameters up to 8 days after multiple doses of Apixaban were administered.
| h*ng/mL | Part B - LT3001 and Apixaban |
|---|---|
| Plasma PK Parameters of Apixaban - AUC | 593.8 ± 26.7 |
Plasma concentrations of Dabigatran and derived PK parameters up to 8 days after multiple doses of Dabigatran were administered.
| ng/mL | Part B - LT3001 and Dabigatran |
|---|---|
| Plasma PK Parameters of Dabigatran - Cmax | 146.1 ± 30.77 |
Plasma concentrations of Dabigatran and derived PK parameters up to 8 days after multiple doses of Dabigatran administered (alone or with LT3001).
| hour | Part B - LT3001 and Dabigatran |
|---|---|
| Plasma PK Parameters of Dabigatran - Tmax | 4.1 ± 1.2 |
Plasma concentrations of Dabigatran and derived PK parameters up to 8 days after multiple doses of Dabigatran administered (alone or with LT3001).
| h*ng/mL | Part B - LT3001 and Dabigatran |
|---|---|
| Plasma PK Parameters of Dabigatran - AUC | 1807 ± 405.3 |
Collected over Adverse events were assessed from baseline through Day 4 post-baseline in Part A, and from baseline through Day 16 post-baseline in Part B.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A - LT3001 Drug Product | 0/12 (0%) | 0/12 (0%) | 3/12 (25%) |
| Part A - Placebo | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| Part B - LT3001 and Aspirin | 0/12 (0%) | 0/12 (0%) | 2/12 (16.7%) |
| Part B - LT3001 and Clopidogrel | 0/12 (0%) | 0/12 (0%) | 2/12 (16.7%) |
| Part B - LT3001 and Apixaban | 0/12 (0%) | 0/12 (0%) | 2/12 (16.7%) |
| Part B - LT3001 and Dabigatran | 0/12 (0%) | 0/12 (0%) | 1/12 (8.3%) |
| Event | Part A - LT3001 Drug Product | Part A - Placebo | Part B - LT3001 and Aspirin | Part B - LT3001 and Clopidogrel | Part B - LT3001 and Apixaban | Part B - LT3001 and Dabigatran |
|---|---|---|---|---|---|---|
| Abdominal painGastrointestinal disorders | 1/12 | 0/4 | 0/12 | 2/12 | 0/12 | 0/12 |
| HeadacheNervous system disorders | 1/12 | 0/4 | 0/12 | 2/12 | 0/12 | 0/12 |
| Menstruation irregularEndocrine disorders | 1/12 | 0/4 | 0/12 | 0/12 | 0/12 | 0/12 |
| Oral herpesInfections and infestations | 1/12 | 0/4 | 0/12 | 0/12 | 0/12 | 0/12 |
| NauseaGastrointestinal disorders | 0/12 | 0/4 | 0/12 | 1/12 | 0/12 | 0/12 |
| VomitingGastrointestinal disorders | 0/12 | 0/4 | 1/12 | 0/12 | 0/12 | 0/12 |
| Thoracic outlet syndromeNervous system disorders | 0/12 | 0/4 | 1/12 | 0/12 | 0/12 | 0/12 |
| InfluenzaInfections and infestations | 0/12 | 0/4 | 1/12 | 0/12 | 0/12 | 0/12 |
| ContusionInjury, poisoning and procedural complications | 0/12 | 0/4 | 0/12 | 0/12 | 1/12 | 0/12 |
| Back painMusculoskeletal and connective tissue disorders | 0/12 | 0/4 | 0/12 | 0/12 | 1/12 | 0/12 |
| Age, Categorical(Participants) | Part A - LT3001 Drug Product | Part A - Placebo | Part B - LT3001 and Aspirin | Part B - LT3001 and Clopidogrel | Part B - LT3001 and Apixaban | Part B - LT3001 and Dabigatran | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 12 | 4 | 13 | 12 | 12 | 12 | 65 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(year) | Part A - LT3001 Drug Product | Part A - Placebo | Part B - LT3001 and Aspirin | Part B - LT3001 and Clopidogrel | Part B - LT3001 and Apixaban | Part B - LT3001 and Dabigatran | Total |
|---|---|---|---|---|---|---|---|
| Median | 35.5 (25 to 57) | 43.5 (22 to 54) | 45 (31 to 64) | 42.5 (28 to 61) | 45.5 (21 to 65) | 55 (30 to 62) | 42 (21 to 65) |
| Sex: Female, Male(Participants) | Part A - LT3001 Drug Product | Part A - Placebo | Part B - LT3001 and Aspirin | Part B - LT3001 and Clopidogrel | Part B - LT3001 and Apixaban | Part B - LT3001 and Dabigatran | Total |
|---|---|---|---|---|---|---|---|
| Female | 7 | 3 | 7 | 6 | 5 | 7 | 35 |
| Male | 5 | 1 | 6 | 6 | 7 | 5 | 30 |
| Race (NIH/OMB)(Participants) | Part A - LT3001 Drug Product | Part A - Placebo | Part B - LT3001 and Aspirin | Part B - LT3001 and Clopidogrel | Part B - LT3001 and Apixaban | Part B - LT3001 and Dabigatran | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 6 | 2 | 0 | 0 | 2 | 1 | 11 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 5 | 5 | 2 | 3 | 17 |
| White | 5 | 1 | 8 | 7 | 6 | 8 | 35 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 2 | 0 | 2 |
| Region of Enrollment(participants) | Part A - LT3001 Drug Product | Part A - Placebo | Part B - LT3001 and Aspirin | Part B - LT3001 and Clopidogrel | Part B - LT3001 and Apixaban | Part B - LT3001 and Dabigatran | Total |
|---|---|---|---|---|---|---|---|
| United States | 12 | 4 | 13 | 12 | 12 | 12 | 65 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2021 to primary completion in Aug 2021, 4 months.
Results were first posted in Feb 2026, 4 years 6 months after primary completion.
Of 42 phase 1 interventional studies under Ischemic Stroke, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 4 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: LT3001
Lumosa Therapeutics Co., Ltd.